Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine, Cannabidiol and Cobicistat Interaction Study
NCT07462559Phase 1Not yet recruiting
- Sponsor
- Helsinki University Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ketamine in treatment-resistant depression (TRD) (4 arms), sponsored by Helsinki University Hospital. Primary endpoint: Area Under the Curve of Ketamine at 23 hours. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07462559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462559.